Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Jul 29;11(8):1071.
doi: 10.3390/cancers11081071.

Immunotherapy in Hodgkin Lymphoma: Present Status and Future Strategies

Theodoros P Vassilakopoulos  1 , Chrysovalantou Chatzidimitriou  2 , John V Asimakopoulos  2 , Maria Arapaki  2 , Evangelos Tzoras  2 , Maria K Angelopoulou  2 , Kostas Konstantopoulos  2
Affiliations
Review

Immunotherapy in Hodgkin Lymphoma: Present Status and Future Strategies

Theodoros P Vassilakopoulos et al. Cancers (Basel). .

Abstract

Although classical Hodgkin lymphoma (cHL) is usually curable, 20-30% of the patients experience treatment failure and most of them are typically treated with salvage chemotherapy and autologous stem cell transplantation (autoSCT). However, 45-55% of that subset further relapse or progress despite intensive treatment. At the advanced stage of the disease course, recently developed immunotherapeutic approaches have provided very promising results with prolonged remissions or disease stabilization in many patients. Brentuximab vedotin (BV) has been approved for patients with relapsed/refractory cHL (rr-cHL) who have failed autoSCT, as a consolidation after autoSCT in high-risk patients, as well as for patients who are ineligible for autoSCT or multiagent chemotherapy who have failed ≥ two treatment lines. However, except of the consolidation setting, 90-95% of the patients will progress and require further treatment. In this clinical setting, immune checkpoint inhibitors (CPIs) have produced impressive results. Both nivolumab and pembrolizumab have been approved for rr-cHL after autoSCT and BV failure, while pembrolizumab has also been licensed for transplant ineligible patients after BV failure. Other CPIs, sintilimab and tislelizumab, have been successfully tested in China, albeit in less heavily pretreated populations. Recent data suggest that the efficacy of CPIs may be augmented by hypomethylating agents, such as decitabine. As a result of their success in heavily pretreated disease, BV and CPIs are moving to earlier lines of treatment. BV was recently licensed by the FDA for the first-line treatment of stage III/IV Hodgkin lymphoma (HL) in combination with AVD (only stage IV according to the European Medicines Agency (EMA)). CPIs are currently being evaluated in combination with AVD in phase II trials of first-line treatment. The impact of BV and CPIs was also investigated in the setting of second-line salvage therapy. Finally, combinations of targeted therapies are under evaluation. Based on these exciting results, it appears reasonable to predict that an improvement in survival and a potential increase in the cure rates of cHL will soon become evident.

Keywords: Hodgkin lymphoma; brentuximab vedotin; nivolumab; pembrolizumab; refractory; relapsed.

PubMed Disclaimer

Conflict of interest statement

T.P.V. declares participation in advisory boards and receiving honoraria from ROCHE, B.M.S., M.S.D. and Takeda; M.K.A. declares participation in advisory boards and receiving honoraria from ROCHE, B.M.S., and Takeda; K.K. declares research support from ROCHE and Takeda. All other authors declare no conflicts of interest.

References

    1. Osterborg A., Dyer M.J., Bunjes D., Pangalis G.A., Bastion Y., Catovsky D., Mellstedt H. Phase II Multicenter Study of Human Cd52 Antibody in Previously Treated Chronic Lymphocytic Leukemia. European Study Group of Campath-1H Treatment in Chronic Lymphocytic Leukemia. J. Clin. Oncol. 1997;15:1567–1574. doi: 10.1200/JCO.1997.15.4.1567. - DOI - PubMed
    1. Pangalis G.A., Dimopoulou M.N., Angelopoulou M.K., Tsekouras C., Vassilakopoulos T.P., Vaiopoulos G., Siakantaris M.P. Campath-1H (Anti-CD52) Monoclonal Antibody Therapy in Lymphoproliferative Disorders. Med. Oncol. 2001;18:99–107. doi: 10.1385/MO:18:2:99. - DOI - PubMed
    1. Falchi L., Ferrajoli A., Jacobs I., Nava-Parada P. An Evidence-Based Review of Anti-Cd20 Antibody-Containing Regimens for the Treatment of Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia, Diffuse Large B-Cell Lymphoma, or Follicular Lymphoma. Clin. Lymphoma Myeloma Leuk. 2018;18:508–518. doi: 10.1016/j.clml.2018.05.009. - DOI - PubMed
    1. Coiffier B., Lepage E., Briere J., Herbrecht R., Tilly H., Bouabdallah R., Morel P., van den Neste E., Salles G., Gaulard P., et al. CHOP Chemotherapy Plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma. N. Engl. J. Med. 2002;346:235–242. doi: 10.1056/NEJMoa011795. - DOI - PubMed
    1. Salles G., Seymour J.F., Offner F., Lopez-Guillermo A., Belada D., Xerri L., Feugier P., Bouabdallah R., Catalano J.V., Brice P., et al. Rituximab Maintenance for 2 Years in Patients with High Tumour Burden Follicular Lymphoma Responding to Rituximab Plus Chemotherapy (PRIMA): A Phase 3, Randomised Controlled Trial. Lancet. 2011;377:42–51. doi: 10.1016/S0140-6736(10)62175-7. - DOI - PubMed